Exhibit 99.1 Xencor Reports Fourth Quarter and Full Year 2023 Financial Results -- Clinical development focus on high-potential XmAb® T cell engagers and selective dual checkpoint inhibitor, vudalimab - - -- Vudalimab (PD-1 x CTLA-4) monotherapy generally well tolerated with encouraging clinical benefit for patients with high-risk mCRPC who have advanced beyond standard of care therapy -- -- Management to Host Conference Call at 4:30 p.m. ET Today -- PASADENA, Calif.--Feb. 27, 2024-- Xencor, Inc. (NASDAQ:XN ...